241 related articles for article (PubMed ID: 38259435)
1. Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia model.
Curran CS; Cui X; Li Y; Jeakle M; Sun J; Demirkale CY; Minkove S; Hoffmann V; Dhamapurkar R; Chumbris S; Bolyard C; Iheanacho A; Eichacker PQ; Torabi-Parizi P
Front Immunol; 2023; 14():1308358. PubMed ID: 38259435
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-L1 Therapy Does Not Improve Survival in a Murine Model of Lethal Staphylococcus aureus Pneumonia.
Curran CS; Busch LM; Li Y; Xizhong C; Sun J; Eichacker PQ; Torabi-Parizi P
J Infect Dis; 2021 Dec; 224(12):2073-2084. PubMed ID: 34009385
[TBL] [Abstract][Full Text] [Related]
3. Establishment of Anti-Dog Programmed Cell Death Ligand 1 Monoclonal Antibodies for Immunohistochemistry.
Ouchida T; Suzuki H; Tanaka T; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2024 Feb; 43(1):17-23. PubMed ID: 38237003
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S; Truntzer C; Perrichet A; Limagne E; Fumet JD; Richard C; Elkrief A; Routy B; Rébé C; Ghiringhelli F
Oncoimmunology; 2020 Oct; 9(1):1836766. PubMed ID: 33178495
[TBL] [Abstract][Full Text] [Related]
5. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
6. Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L
Yamada S; Itai S; Kaneko MK; Kato Y
Biochem Biophys Rep; 2018 Mar; 13():123-128. PubMed ID: 29556567
[TBL] [Abstract][Full Text] [Related]
7. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibody L
Yamada S; Itai S; Nakamura T; Yanaka M; Chang YW; Suzuki H; Kaneko MK; Kato Y
Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):110-115. PubMed ID: 29608408
[TBL] [Abstract][Full Text] [Related]
9. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
10. Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection.
Chen Y; Wu S; Guo G; Fei L; Guo S; Yang C; Fu X; Wu Y
PLoS Pathog; 2011 Jul; 7(7):e1001347. PubMed ID: 21750671
[TBL] [Abstract][Full Text] [Related]
11. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
15. GM-CSF derived from the inflammatory microenvironment potentially enhanced PD-L1 expression on tumor-associated macrophages in human breast cancer.
Yonemitsu K; Pan C; Fujiwara Y; Miyasato Y; Shiota T; Yano H; Hosaka S; Tamada K; Yamamoto Y; Komohara Y
Sci Rep; 2022 Jul; 12(1):12007. PubMed ID: 35835809
[TBL] [Abstract][Full Text] [Related]
16. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
17. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
18. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
19. The role of the PD-1/PD-L1 axis in macrophage differentiation and function during pregnancy.
Zhang Y; Ma L; Hu X; Ji J; Mor G; Liao A
Hum Reprod; 2019 Jan; 34(1):25-36. PubMed ID: 30500923
[TBL] [Abstract][Full Text] [Related]
20. [The Mechanism of PD-L1 Expression and the Development of Biomarker of Anti-PD-1/Anti-PD-L1 Monoclonal Antibody from the Viewpoint of IFN-γ].
Nakayama Y; Mimura K; Kono K
Gan To Kagaku Ryoho; 2019 May; 46(5):838-840. PubMed ID: 31189799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
